Virco News

  As part of Virco's ongoing support and development of its pharmaceutical research services to the industry, we are pleased to inform you a publication on our hepatitis C subtyping assay (Koletzki D, et al; Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay; Clin Chem and Lab Medicine 2010;...

  Advanced Biologic Laboratories (ABL), a Luxembourg-based global health information technology company dedicated to deliver healthcare products and services to enable its customers to optimize their HIV healthcare services, has signed a non-exclusive international distribution agreement (excluding United States, Australia, Canada and the United Kingdom) to incorporate Virco BVBA's virco®TYPE HIV-1 resistance interpretation...

  Virco will now provide HIV drug-resistance testing to the UK & Ireland via a new agreement with Lab21, the Cambridge-based specialist in personalised medicine testing, with Lab21 performing HIV genotyping services in its own laboratory using Virco protocols, whilst Virco will provide the virco®TYPE HIV-1 via Lab21 as its...

  Due to declining demand for the Antivirogram® in the US and other markets, Virco BVBA announced that as of April 26th, 2010, it will no longer offer this service for routine clinical use. The test will remain available for research and the drug discovery and development market. “Growing acceptance...

Tibotec Virco Virology BVBA Acquires LAB TRACKER™ HIV Electronic Medical Record Software System from Ground Zero Software   Tibotec Virco Virology BVBA today announced the acquisition of LAB TRACKER™ HIV, a customized electronic medical record (EMR) system, from the company Ground Zero Software. LAB TRACKER™ HIV is a full-service, scalable...

HIV-1 resistance testing has become the standard-of-care for managing treatment-experienced patients and is increasingly recommended for treatment-naïve patients. The two standard methods for resistance testing are genotyping, which is generally used in treatment-naïve patients and where relatively simple resistance patterns are expected, and phenotyping, which is more commonly used in...

Focused relationship will allow both infrastructure development and research to gain better understanding of HIV drug resistance and patient outcomes  Virco BVBA is pleased to announce the signing of their first collaboration agreement with KompetenzNetz HIV/AIDS, a German research network for HIV/AIDS representing a cohort of over 8,000 HIV patients...

Volume 1 Number 1 click here...

  The Poster "Phenotypic Data to Guide Selection of RTI in Second Line Therapy following Extended Virological Failure in Uganda", with authors from the MRC, several African centers, and Virco, received one of two awards for best posters at the IHDRW awards dinner. The first author, Dr N Ndembi, from the...

  Virco BVBA signs Hepatitis C licensing agreement with Siemens Healthcare Diagnostics Inc. Mechelen, Belgium, 28 May 2009: Virco BVBA has today signed a global research and development, non-exclusive licensing agreement with Siemens Healthcare Diagnostics Inc (NY, USA). Under this agreement Siemens is providing Virco a license which will enable...